News from essa pharma inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 10, 2022, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel ...

Apr 26, 2022, 16:30 ET ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing ...

Apr 08, 2022, 13:00 ET ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders...

Mar 10, 2022, 16:05 ET ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

South San Francisco, California and Vancouver, Canada, March 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing ...

Mar 09, 2022, 23:34 ET ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing...

Mar 08, 2022, 16:30 ET ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANITen bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of...

Feb 03, 2022, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Jan 19, 2022, 07:00 ET ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

Nov 18, 2021, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Nov 08, 2021, 07:00 ET ESSA Pharma to Participate in Three Upcoming Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Oct 28, 2021, 16:05 ET ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

VANCOUVER, Canada and HOUSTON, Texas, Oct. 28, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Oct 07, 2021, 09:00 ET ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386

- Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics – VANCOUVER, Canada and HOUSTON, Texas, Oct. 7, 2021 /CNW/ - ESSA Pharma Inc. ...

Aug 31, 2021, 16:05 ET ESSA Pharma to Present at Upcoming September Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Aug 16, 2021, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021

HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

May 25, 2021, 07:00 ET ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

HOUSTON, Texas and VANCOUVER, Canada, May 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for ...

May 06, 2021, 07:01 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public...

Apr 28, 2021, 07:00 ET ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

HOUSTON, Texas and VANCOUVER, Canada, April 28, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies...

Apr 14, 2021, 07:00 ET ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Apr 10, 2021, 08:30 ET ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new...

Mar 26, 2021, 16:05 ET ESSA Announces Change to its Board of Directors

HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

Mar 04, 2021, 11:32 ET ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

VANCOUVER, BC and HOUSTON, March 4, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

Feb 25, 2021, 18:33 ET ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies...

Feb 25, 2021, 16:30 ET ESSA Pharma to Present at Upcoming March Investor Conferences

HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

Feb 25, 2021, 07:00 ET ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies...

Feb 22, 2021, 11:48 ET ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock

VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...